PEOPLE - Bioject (US) makes appointment:
This article was originally published in Clinica
Developer of needle-free drug delivery systems Bioject (Bedminster, New Jersey) has appointed Eric Mishkin as senior vice-president and chief scientific officer. Dr Mishkin, who has over 25 years of experience in immunology research and microbiology, most recenly served as director of immunology research at Wyeth-Ayerst. It has also announced the appointment of Chris Pugh, who has over 10 years of product and business development experience, as director of business development.
You may also be interested in...
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.